Table 1 Sample characteristics (Group I) stratified by serostatus.

From: Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

Serostatus

N

Age (y)

Sex (f)

Education (high)

BMI

Number of comorbidities

Number of symptoms

ELISA−

4673

55.2 (13.6)

0.57

0.54

25.6 (4.5)

1.1 (1.4)

5.8 (4.9)

ELISA±/IFT−/PRNT−

33

58.5 (14.6)

0.36

0.55

25.0 (3.9)

1.1 (1.2)

6.2 (5.1)

ELISA±/IFT+/PRNT−

2

58.0 (8.5)

1.00

0.00

27.1 (5.5)

1.5 (0.7)

3.5 (3.5)

ELISA±/IFT+/PRNT+

1

44

1

30.5

13

ELISA+/IFT−/PRNT−

23

54.6 (13.5)

0.52

0.74

25.3 (5.4)

1.0 (0.9)

5.6 (3.6)

ELISA+/IFT+/PRNT−

7

63.7 (20.9)

0.57

0.43

28.3 (6.2)

1.1 (1.1)

5.6 (3.4)

ELISA+/IFT+/PRNT+

16

52.5 (15.4)

0.69

0.62

23.6 (2.1)

0.9 (0.9)

9.5 (6.2)

Missing

16

56.4 (9.7)

0.69

0.50

28.6 (6.3)

1.4 (1.3)

4.2 (4.3)

  1. Values represent means (standard deviation) for continuous variables and fractions for categorical variables.
  2. BMI body mass index, f female, IFT immunofluorescence test, PRNT plaque reduction neutralization test, y years.